Coeptis Therapeutics, Inc.
General ticker "COEP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $59.8M (TTM average)
Coeptis Therapeutics, Inc. follows the US Stock Market performance with the rate: 0.8%.
Estimated limits based on current volatility of 9.5%: low 6.57$, high 8.32$
Factors to consider:
- Total employees count: 6 (-14.3%) as of 2025
- Top business risk factors: Going concern doubt, Insufficient capital, Clinical trial failure, Regulatory and compliance, Labor/talent shortage/retention
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.12$, 23.26$]
- 2026-12-31 to 2027-12-31 estimated range: [3.96$, 14.32$]
Financial Metrics affecting the COEP estimates:
- Positive: with PPE of -5.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 83.95 > 64.23
- Positive: Interest expense per share per price, % of 0.15 <= 0.74
- Positive: Inventory ratio change, % of -30.55 <= -0.75
Short-term COEP quotes
Long-term COEP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $1.36MM |
| Operating Expenses | $21.49MM | $10.05MM | $14.41MM |
| Operating Income | $-21.49MM | $-10.05MM | $-13.04MM |
| Non-Operating Income | $0.22MM | $-0.82MM | $0.77MM |
| Interest Expense | $0.11MM | $0.25MM | $0.10MM |
| R&D Expense | $6.67MM | $2.33MM | $1.28MM |
| Income(Loss) | $-21.27MM | $-10.88MM | $-12.28MM |
| Net Income(Loss)* | $-21.27MM | $-10.68MM | $-11.92MM |
| Stockholders Equity | $0.81MM | $3.38MM | $13.56MM |
| Assets | $4.57MM | $8.91MM | $16.15MM |
| Operating Cash Flow | $-7.24MM | $-6.65MM | $-8.60MM |
| Financing Cash Flow | $4.92MM | $5.71MM | $13.74MM |
| Earnings Per Share** | $-0.83 | $-5.55 | $-2.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.